Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
ML141
Cat. No.:
OB0225LY-0045
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
ML141 is a selective inhibitor that targets the small GTPase Cdc42.
Synonym:
71203-35-5; ML 141; ML-141; 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide; 4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonamide
CAS No.:
71203-35-5
Compound CID:
2950007
Formula:
C22H21N3O3S
Formula Weight:
407.49
Specification
Relative Density:
1.31 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
ML141 plays an important role in the study of cell migration, tumorigenesis and metastasis mechanisms.
Library Information
Targets:
Ras; CDK
Receptors:
cdc42; Ras
Pathways:
GPCR/G protein; Apoptosis; MAPK; Cell cycle/Checkpoint
Plate Number:
AOCL-1
Plate Location:
e7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
65 mg/mL; 159.51 mM
